Technology
Health
Biotechnology

TRACON Pharmaceuticals

$1.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-4.26%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell TCON and other stocks, options, ETFs, and crypto commission-free!

About

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. Read More The company was founded in October 2004 and is headquartered in San Diego, CA.

Employees
26
Headquarters
San Diego, California
Founded
2004
Market Cap
42.12M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
218.72K
High Today
$1.45
Low Today
$1.34
Open Price
$1.41
Volume
86.29K
52 Week High
$3.20
52 Week Low
$0.50

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
Biopharmaceutical
Therapy
Pharmaceutical

News

MarketBeatMar 11

Stock Price, News, & Analysis for TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carc...

232
Simply Wall StMar 2

How Much Of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Do Insiders Own?

A look at the shareholders of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, β€˜Don’t tell me what you think, tell me what you have in your portfolio.’ TRACON Pharmaceuticals is not a large company by global standards. It has a market capit...

157
Seeking AlphaFeb 28

TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q4 2018 Results - Earnings Call Transcript

TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Director, Controller Conference Call Participants Maury Raycroft - Jefferies Jake Colby - BTIG Nick Abbot - Wells Fargo Operator Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Fourth Quarter and Year-End 2018 Earnings Conference Call. At this time, all callers are in a listen-only ...

252

Earnings

-$0.46
-$0.28
-$0.11
$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.